Clinical Pharmacology of Trimethoprim-Sulfamethoxazole in Paediatric Patients
New Medical Innovations and Research · 2023
DOI: 10.31579/2767-7370/043 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Medical Innovations and Research, 2023. Verfasst von Gian Maria Pacifici.
Abstract (Originalsprache)
Trimethoprim-sulfamethoxazole is the sulphonamide used in paediatric patients. Trimethoprim-sulfamethoxazole is available as a single-entity preparation and its introduction in clinic has been an important advance in treatment of bacterial infections. Trimethoprim inhibits bacterial dihydrofolate reductase an enzyme downstream form the one that sulphonamides inhibit in the same biosynthetic sequence. This formulation consists in a ratio of sulfamethoxazole:trimethoprin 20:1, may be bactericidal, and in-vivo concentration of sulfamethoxazole is 20-times greater than that of trimethoprim. Trimethoprim-sulfamethoxazole is active against most strains of Staphylococcus aureus and Staphylococcus epidermis, even among methicillin-resistant isolates, viridians group of streptococci, Escherichia coli, Proteus mirabilis, Klebsiella and Enterobacter species, Salmonella, Pseudomonas pseudomallei, Serratia species, Brucella abortus, Pasteurella haemolytica, Yersinia pseudotuberculosis, Yersinia enterocolitica, and Nocardia asteroides. Trimethoprim-sulfamethoxazole has been found efficacy and safe in children but may induce adverse-effects. Both trimethoprim and sulfamethoxazole are rapidly absorbed following oral administration and their absorption-rate constant is 1.27 and 0.58 h-1, respectively. Trimethoprim and sulfamethoxazole inhibits CYP2C8 and CYP2C9, respectively. Prophylaxis and treatment with trimethoprim-sulfamethoxazole have been reviewed and this drug combination treated the meningitis caused by Listeria monocytogenes, Elizabethkingia, Nocardia meningitis, Elizabethkingia meningoseptica, and Staphylococcus aureus. Trimethoprim and sulfamethoxazole are poorly transferred across the human placenta and poorly migrate into the breast-milk. The aim of this study is to review trimethoprim-sulfamethoxazole dosing, efficacy and safely, adverse-effects, interaction with drugs, prophylaxis, treatment and treatment of bacterial meningitis and trimethoprim and sulfamethoxazole pharmacokinetics, penetration into the cerebrospinal fluid, transfer across the human placenta, and migration into the breast-milk.
Zitieren
APA
Pacifici, G. M. (2023). Clinical Pharmacology of Trimethoprim-Sulfamethoxazole in Paediatric Patients. New Medical Innovations and Research. https://doi.org/10.31579/2767-7370/043
Vancouver
Pacifici GM. Clinical Pharmacology of Trimethoprim-Sulfamethoxazole in Paediatric Patients. New Medical Innovations and Research. 2023. doi:10.31579/2767-7370/043
BibTeX
@article{Pacifici2023,
author = {Pacifici, Gian Maria},
title = {Clinical Pharmacology of Trimethoprim-Sulfamethoxazole in Paediatric Patients},
journal = {New Medical Innovations and Research},
year = {2023},
doi = {10.31579/2767-7370/043}
}
EUVIMED